Mutations in the PTEN tumor suppressor gene are found in a high proportion of human prostate cancers, and in mice, Pten deletion induces high-grade prostate intraepithelial neoplasia (HGPIN). However, progression from HGPIN to invasive cancer occurs slowly, suggesting that tumorigenesis is subject to restraint. We show that Pten deletion, or constitutive activation of the downstream kinase AKT, activates the transforming growth factor (TGF)b pathway in prostate epithelial cells. TGFb signaling is known to have a tumor suppressive role in many cancer types, and reduced expression of TGFb receptors correlates with advanced human prostate cancer. We demonstrate that in combination either with loss of Pten or expression of constitutively active AKT1, inactivation of TGFb signaling by deletion of the TGFb type II receptor gene relieves a restraint on tumorigenesis. This results in rapid progession to lethal prostate cancer, including metastasis to lymph node and lung. In prostate epithelium, inactivation of TGFb signaling alone is insufficient to initiate tumorigenesis, but greatly accelerates cancer progression. The activation of TGFb signaling by Pten loss or AKT activation suggests that the same signaling events that have key roles in tumor initiation also induce the activity of a pathway that restrains disease progression.
INTRODUCTION
Deletions or mutations in PTEN are found in 30% of primary human prostate cancers, and in more than 60% of prostate cancer metastases. [1] [2] [3] [4] A major consequence of Pten loss is deregulated phosphatidylinositide 3-kinase signaling, leading to the activation of Akt/PKB, an oncogenic kinase that promotes cell growth, proliferation and survival. 5, 6 Although homozygous deletion of Pten in mice is embryonically lethal, animals with heterozygous loss of function develop tumors in multiple tissues, including the prostate. 7, 8 Conditional deletion of Pten in mouse prostate activates Akt signaling and causes focal prostate intraepithelial neoplasia (PIN) by 6 weeks and high-grade prostate intraepithelial neoplasia (HGPIN) by 8-9 weeks. These mice develop locally invasive tumors by 6-12 months but usually survive beyond 1 year of age. [9] [10] [11] [12] Homozygous deletion of Akt1 slows the development of HGPIN in Pten heterozygous mice, and reducing levels of PDK1, which is required for activation of Akt, also slows tumor formation in Pten heterozygotes. 13, 14 Akt signaling is, therefore, a major mediator of the tumorigenic effects of Pten loss. A transgenic line in which constitutively active human AKT1 (caAKT1) is expressed from the rat probasin promoter develops HGPIN with high penetrance, but these tumors do not become invasive. 15, 16 Thus, while Akt is a key driver of the HGPIN phenotype induced by loss of Pten, additional factors are required for progression to invasive cancer. In addition, while homozygous loss of Pten efficiently initiates prostate tumorigenesis, tumors in these mice progress beyond HGPIN relatively slowly, suggesting the presence of pathways that limit tumor progression.
Transforming growth factor (TGF) b ligands assemble a complex of type I and type II receptors, in which the type II receptor phosphorylates and activates the type I receptor. [17] [18] [19] The activated type I receptor phosphorylates receptor Smads (R-Smad), primarily Smad2 and Smad3 in response to TGFb, and phosphorylated R-Smad/Smad4 complexes accumulate in the nucleus to regulate gene expression. 20 In many cell types, including epithelial cells, TGFb signaling via Smad2/3 inhibits cell proliferation and has a tumor suppressive role. 21, 22 Mutations in the TGFb type I and type II receptor (TGFBR1 and 2) genes are observed in human prostate cancer, 23 and reduced expression of SMAD4 and TGFBR2 correlates with advanced prostate cancer. 24, 25 A reduction in the expression of TGFBR1 and TGFBR2 has been reported in up to 25% and 12.5%, respectively, of human prostate cancers, and reduced TGFBR2 expression was also shown to correlate with decreased survival. 23, [26] [27] [28] In mice, the combination of prostate-specific homozygous Pten deletion with homozygous mutations in Smad4, which encodes a mediator of TGFb family signaling, has been shown to drive aggressive prostate tumors. 29 Taken together with elevated cyclin D and Spp1 expression, reduced expression of Pten and Smad4 was suggested to be predictive of human prostate cancer severity. In addition, in a mouse prostate cancer model with telomere dysfunction and genomic instability, deletion of the Smad4 gene was seen in a significant proportion of tumors. 30 Thus, TGFb signaling is likely a key regulator of prostate cancer progression.
Here, we show that deletion of Pten or expression of constitutively active AKT1 in the prostate results in the induction of multiple components of the TGFb pathway. Homozygous deletion of Tgfbr2 specifically in prostate epithelial cells in the background of a Pten mutation results in the rapid onset of poorly differentiated adenocarcinoma (PDA) of the prostate that is refractory to castration. Microinvasive cancer is evident as early as 8 weeks after birth, and animals lacking both Pten and Tgfbr2 from the prostate develop lymph node and lung metastases. Finally, we provide evidence that the combination of constitutive Akt activation together with inactivation of TGFb signaling is sufficient to generate invasive cancer in the prostate.
RESULTS
Early onset of lethal prostate cancer in the absence of both Pten and Tgfbr2 To test whether deletion of the Tgfbr2 gene affected prostate cancer progression in mice, we combined conditional alleles of the Tgfbr2 31 and Pten genes 10 with the prostate epitheliumspecific CRE transgene (Pb-Cre4; Wu et al. 32 ). Analysis of mouse prostate tissue by immunohistochemistry (IHC) revealed relatively low-level expression of Tgfbr2 in the prostate epithelium, which was lost with the conditional Tgfbr2 allele and the Pb-Cre4 transgene (Figure 1a) . To confirm the effects of loss of Pten, we stained wild-type and conditional Pten-null prostate with an antibody that recognizes Akt phosphorylated on serine 473, as a mark of Akt activation. Little or no phospho-Akt signal was seen in the control, whereas Akt activation was clearly present in the conditional Pten-null prostate ( Figure 1a ). We next generated males with homozygous deletion of both genes in the prostate (referred to as Pten r/r ;Tgfbr2 r/r ). From 32 Pten r/r ;Tgfbr2 r/r male mice, none survived past 20 weeks of age, median survival time was o13 weeks (88 days) and five animals were required to be killed before 11 weeks of age (Figures 1b and e ;Tgfbr þ /r mice, there was a significant increase in the incidence of invasive cancer in the Pten þ /r ;Tgfbr2 r/r mice, with a concomitant decrease in median survival to o49 weeks (Figure 1d ). Pten þ /r ;Tgfbr2 r/r mice developed large prostate tumors similar to those seen in double nulls (Figures 1c and e) . The effect of homozygous Tgfbr2 deletion on the survival of Pten-null and Pten heterozygous animals was highly significant, demonstrating a dramatic synergistic effect of deleting both Tgfbr2 and Pten in the prostate (Figures 1b and d) . In addition, even a heterozygous mutation in the Tgfbr2 gene resulted in more rapid onset of severe tumors in a Pten-null background, reducing the median survival time by almost 6 months ( Figure 1e ).
Invasive adenocarcinoma in Pten r/r ;Tgfbr2 r/r prostates Histological analysis of prostates from Tgfbr2 r/r mice did not reveal any differences compared with wild-type animals, even beyond 1 year of age ( Figure 2 and data not shown). By 8 weeks of age, both Pten r/r and Pten r/r ;Tgfbr2 r/r animals had developed HGPIN with 100% penetrance (Figure 2 ). Regions of microinvasive cancer were evident in the majority of Pten r/r ;Tgfbr2 r/r prostates as early as 8 weeks of age, and by 12-14 weeks, this had progressed to PDA, ;Tgfbr2 r/r animals, with higher cyclin D levels in invasive cancer than adjacent HGPIN or normal ducts, and the converse for p27 (Figure 3e ). Thus, increased proliferation appears to correlate with phenotype as the tumors progress from HGPIN to invasive cancer in the double-null animals.
Castration-resistant metastasis in the double-null animals We examined the lumbar lymph nodes for metastases from 50 Pten r/r mice with different Tgfbr2 genotypes. Only one of six Ptennull mice had a lymph node micrometastasis, whereas 23 out of 35 Pten r/r ;Tgfbr2 r/r mice had lymph node metastases, as well as all nine of the Pten r/r ;Tgfbr2 þ /r mice examined (Figure 4a ). In addition, four of the 11 Pten þ /r ;Tgfbr2 r/r animals examined had lymph node metastases, most of which were relatively small, but could be readily confirmed by staining for keratin 18 (Figures 4b  and c) . Lymph node metastases were found in a high proportion of Pten mutant animals that also had mutations in Tgfbr2, suggesting that impaired TGFb signaling in the context of a Pten mutation can promote invasion and metastasis. We also examined other tissues in a subset of mice that were positive for lymph node metastasis. Lung metastases were found in all four Pten r/r ;Tgfbr2 þ /r mice examined, and at a lower frequency (6 out of 11) in Pten r/r ; Tgfbr2 r/r mice ( Figure 4d ). As with lymph node, the majority of lung metastases were very small, although one much larger metastasis was found in a Pten r/r ;Tgfbr2 þ /r mouse (Figures 4e and f) . Androgen ablation is a common treatment for human prostate cancer that is initially effective at reducing tumor growth. 33 To test whether tumor progression in Pten r/r ;Tgfbr2 r/r mice would respond to castration, we castrated 8 animals at 6 weeks before the onset of adenocarcinoma, and eight at 9-11 weeks of age when the tumors are more advanced. Mice castrated either at 6 weeks or after 9 weeks of age had a median survival time of 93 and 95 days compared with 88 days for the intact animals. Even when combining the data for all castrated animals, there was only a slight rightward shift in the survival curve, which was not significant (Figure 4g ). We also identified lymph node micrometastases in 5 of 14 castrated animals examined (Figure 4a ). Although this is less frequent than in the intact animals, the difference does not reach significance with this number of animals. These data suggest that tumor initiation and progression to invasive metastatic disease in Pten r/r ;Tgfbr2 r/r prostates is insensitive to depletion of testicular androgens. , and smaller increases in Smad2 and Tgfbr1 were observed (Figure 5b ). The increases in Tgfbr2 and Smad4 expression were confirmed at the protein level by western blot (Figure 5c ). To verify that increased expression of TGFb pathway components results in pathway activation, we examined expression of Smad2 phosphorylated at the carboxylterminal receptor phosphorylation site (pSmad2). A clear increase in active pSmad2 was evident in the Pten-null mice (Figure 5c ). To determine whether TGFb signaling to Smad2 changed prostate showed a significant decrease in the pSmad2 N:C ratio, consistent with the loss of Tgfbr2 (Figure 5e ). It should be noted that the pSmad2 level was still higher in the double null than in the wild type, suggesting that signaling ;Tgfbr2 þ /r mouse (f ). (g) Kaplan-Meier plots comparing survival of Pten r/r ;Tgfbr2 r/r with mice of the same genotype that were castrated at 6-11 weeks of age.
via activin type II receptors may drive some Smad2 phosphorylation in the absence of Tgfbr2. Taken together, these data suggest that Pten loss induces upregulation of the TGFb pathway.
Akt activates TGFb signaling Transgenic expression of a myristoylated AKT1 in the prostate (Tg-AKT) results in constitutive AKT1 activity in epithelial cells, and the majority of these mice develop HGPIN, primarily in the ventral prostate. 16 As Akt activation is one of the major outcomes of Pten loss, we tested whether Tg-AKT could induce TGFb pathway activity. High levels of Smad4 expression were evident in Tg-AKT prostate, whereas the expression was much lower in the control (Figure 6a ). Increased expression of Smad4 was observed in regions of the AKT1 transgenic prostate in which pAkt was detectable, and in which the HGPIN phenotype was evident, but not in pAkt-negative samples, in which no phenotype was apparent (Figure 6a ). Analysis of Tgfbr2 and Smad4 by western blot revealed an increase in expression in the AKT transgenic prostate, as well as an increase in pSmad2 levels (Figure 6b ). To test for increased TGFb pathway activity, we analyzed the pSmad2 N:C ratio in two pAkt-positive AKT1 transgenics, as well as in a Pten r/r sample for comparison. We observed significant increases in the pSmad2 N:C ratio in both Tg-AKT samples compared to wild type (Figure 6c ). Taken together, these data suggest that TGFb pathway activation in response to loss of Pten occurs downstream of Akt activation.
We next tested whether prostate cancer progression in the Tg-AKT model is limited by TGFb signaling. Unlike the Pten-null model, HGPIN in Tg-AKT mice does not progress to invasive cancer in the absence of other targeted mutations. 16, 34 We monitored a group of 17 Tg-AKT mice up to 70 weeks of age, of which nine were homozygous null for Tgfbr2. Four of the nine Tgfbr2 r/r were killed before 70 weeks of age, because of tumor burden, whereas all eight mice that were wild type for the receptor survived (Figure 6d ). We found invasive cancer in several Tg-AKT;Tgfbr2 r/r mice, whereas this was not observed in Tg-AKT mice that were wild type for Tgfbr2. HGPIN with high levels of nuclear cyclin D staining was observed in Tg-AKT and Tg-AKT;Tgfbr2 r/r prostates. However, cyclin D staining was further elevated in regions of invasive cancer, in the ventral prostate of Tg-AKT;Tgfbr2 r/r mice, consistent with increased proliferation in these animals ( Figure 6e ). More than 80% of Tg-AKT and Tg-AKT;Tgfbr2 r/r animals had HGPIN after 10 weeks of age (Figure 6f) . However, 5 out of 15 of the phenotypic Tg-AKT;Tgfbr2 r/r animals also had invasive cancer, and this increased to 4 out of 9 among the older animals ( Figure 6f ). Taken together, these data suggest that Akt activation triggers a TGFb-mediated tumor restraint mechanism in prostate epithelium, and that inactivation of this restraint accelerates tumor progression.
DISCUSSION
We found that loss of both Pten and the Tgfbr2 from mouse prostate results in aggressive, castration-resistant cancer with lymph node and lung metastases. Thus, loss of both Pten and Tgfbr2 from mouse prostate appears to recapitulate several features of advanced human prostate cancer, including resistance to androgen depletion and metastasis to distant organs. The most surprising result from our analysis of Tgfbr2;Pten mutants, and from previous work with Smad4;Pten mutants, 30 is that loss of Pten causes upregulation of multiple components of the TGFb pathway, a signaling pathway that restrains tumor progression. Importantly, we show that there is an increase in activated nuclear Smad2 specifically in epithelial cells in Pten-null tumors. In addition, we showed that expression of a constitutively active AKT1 transgene that induces HGPIN, 16 is sufficient to induce Smad4 expression and increase the level of nuclear phosphoSmad2. This suggests that TGFb pathway activation caused by loss of Pten occurs downstream of Akt, rather than other pathways that may be activated by Pten deletion. It is possible that this Aktmediated activation of the TGFb pathway occurs in response to the HGPIN phenotype, rather than as a direct result of Akt activation. However, as more than one component of the TGFb pathway is upregulated by Pten loss, multiple mechanisms may be responsible for the increased expression. Given that prostate cancer can remain indolent for years, it will be of interest to know whether other mutations linked to prostate cancer also activate the TGFb-mediated restraint, and whether an inactivating mutation in the TGFb pathway can promote tumor progression in conjunction with defects in pathways other than the Pten/Akt pathway.
Expression of caAKT1 in mouse prostate induces HGPIN, but these tumors do not progress to invasive cancer. 16, 34 In contrast, in Pten-null prostate HGPIN progresses to invasive cancer, albeit much more slowly than in the presence of an inactivating mutation in the TGFb pathway. Although the TGFb-mediated restraint is activated by caAKT1, and we show that Tgfbr2 deletion is sufficient to allow progression of Tg-AKT tumors to invasive cancer, this still occurs much more slowly than in the Pten-null model. Deletion of Cdkn1b in the context of a heterozygous Pten mutation accelerates tumorigenesis in prostate and other tissues. 35 Similarly, the combination of prostate-specific Tg-AKT with a constitutive Cdkn1b deletion results in a proportion of tumors becoming invasive, although in most cases this occurred only after 1 year of age. 34 We found that homozygous deletion of Tgfbr2 in the context of both prostate epithelium-specific Pten deletion and of Tg-AKT tumors results in progression to invasive cancer, but still with a very different time course. Thus it is likely that, in addition to Akt activation, other pathways activated in response to Pten loss help drive progression to invasive cancer. However, an alternative explanation for this difference is that the expression of myristoylated AKT1 in the prostate is unable to fully recapitulate the effects of AKT activation resulting from Pten deletion.
Our analysis of mice with prostate-specific heterozygous Pten mutations with various Tgfbr2 genotypes supports the idea that loss of Pten is the tumor-initiating event. This is further supported by the fact that mice with homozygous Tgfbr2 deletion in the prostate and wild-type Pten are normal for at least 70 weeks. Although tumors arise in the Pten heterozygous prostates over a relatively long time course, this is consistent with the acquisition of a second mutation that occurs with relatively low frequency, such as inactivation of the other allele of Pten. This has been suggested to be a major route by which Pten heterozygous mutations in mouse prostate can become tumorigenic. 36 All Pten heterozygous tumors analyzed, irrespective of the Tgfbr2 genotype, had high levels of phospho-Akt, specifically in the phenotypic regions of the prostate. In contrast, all Pten heterozygous prostates in which no phenotype was apparent lacked significant phospho-Akt signal. Thus, it is likely that in this context Akt signaling and any other pathways downstream of Pten have been activated by loss of the additional Pten allele. One interesting possibility raised by the low frequency and slow onset of invasive cancer in Tg-AKT;Tgfbr2 r/r mice is that this occurs following the acquisition of some other genetic change, which in combination with AKT activation and inactivation of the TGFb pathway allows for rapid progression to invasive cancer.
We observed a high frequency of metastasis to the local lymph nodes and lungs in animals with reduced TGFb signaling. Given the known prometastatic functions of TGFb signaling, this might be somewhat surprising, although similar increases in metastasis in the Pten;Smad4 double-null model have also been reported. 30 In this context, it is interesting to note that all of the Pten-null mice with heterozygous Tgfbr2 mutations had lymph node metastases, whereas only two-thirds of Pten r/r ;Tgfbr2 r/r mice did. In addition, we identified lung metastases in all four Pten r/r ;Tgfbr2 þ /r mice examined, consistent with the idea that partial inactivation of TGFb signaling might allow for both increased proliferation and increased metastasis. However, an alternative possibility is that more metastases were found in Pten r/r ;Tgfbr2 þ /r mice simply because they survived longer than double nulls.
Conditional Smad4 mutation, in the background of a prostatespecific Pten-null allele, results in prostate tumors in mice, which have a median survival time of o23 weeks. 30 Our analysis of Pten r/r ;Tgfbr2 r/r mice demonstrates the presence of microinvasive cancer as early as 8 weeks of age, and have a median survival time of o13 weeks, suggesting that loss of the Tgfbr2 results in a much more rapid acceleration of tumor progression than with loss of Smad4. This is consistent with the fact that other Smadindependent pathways can be activated downstream of the TGFb receptors. 37, 38 In addition, it is possible that some Smaddependent transcriptional activity is present even in the absence of Smad4. However, it should be noted that while both analyses were carried out in similar mixed strain backgrounds, it is possible that strain differences may contribute to the difference in phenotypes. TGFb signaling can be both antiproliferative and prometastatic, making its role in tumor progression somewhat complex. 21, 22 Therefore, it will be of interest to further dissect how TGFb signaling and the Smads restrain the progression from HGPIN to invasive cancer, and yet promote metastatic disease.
In summary, we have shown that TGFb signaling is induced in the prostate by Pten loss, or by activation of Akt, and functions to keep in check the tumorigenic effects of Pten/Akt pathway activation. This work, together with that analyzing Smad4 and Pten mutations, 30 clearly places TGFb signaling as a key regulator of prostate cancer progression.
MATERIALS AND METHODS

Mice
